Scinai Immunotherapeutics Appoints Eran Kuratz to Streamline CDMO Supply Chain and Operations

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced the appointment of Eran Kuratz as head of supply chain and business process administration for its wholly owned subsidiary, Scinai Biopharma Services Ltd. Kuratz brings more than 30 years of leadership experience in supply chain and operations across the pharmaceutical, biotechnology, medical-device, and industrial sectors. His responsibilities will encompass procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity, and cross-functional business processes.

This strategic hire comes on the heels of Scinai's expansion of its contract development and manufacturing organization (CDMO) platform through the acquisition of Recipharm Israel, slated for the first quarter of 2026. The acquisition added a second development and manufacturing site in Yavne, complementing Scinai's existing operations in Jerusalem. Together, these facilities provide a comprehensive range of capabilities including biologics process development, aseptic manufacturing, sterile fill-and-finish, small-molecule active pharmaceutical ingredient (API) development and synthesis, analytical-method development, and GMP manufacturing.

The appointment of a seasoned executive like Kuratz signals Scinai's focus on optimizing its integrated CDMO services to meet growing demand. With the expanded platform, the company is well-positioned to offer end-to-end solutions to biotech and pharmaceutical clients, from early-stage development through commercial manufacturing. Kuratz's expertise in supply chain and business processes will be instrumental in ensuring operational efficiency, cost-effectiveness, and regulatory compliance across the two sites.

Scinai Immunotherapeutics is a biopharmaceutical company dedicated to developing innovative immunology therapies. Its pipeline includes therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. The company also leverages its CDMO subsidiary to provide development and manufacturing services to external partners, generating revenue and fostering collaborations. The expansion of the CDMO platform and the addition of key personnel like Kuratz underscore Scinai's commitment to becoming a leading player in the contract manufacturing space.

For more information about Scinai Immunotherapeutics and its CDMO services, visit the company's newsroom at https://ibn.fm/SCNI. To view the full press release, visit https://ibn.fm/d9ktl.